Encyclopedia of Heart Diseases

2011 Edition
| Editors: M. Gabriel Khan

Aging and the Heart

Reference work entry
DOI: https://doi.org/10.1007/978-1-60761-219-3_3


The world population of the elderly is approximately 610 million and will grow to approximately 2 billion by 2050. In the year 2000, there were approximately 35 million people in the USA who were 70 years and older. In the year 2030, the number will be approximately 70 million.

There is an epidemic of  heart failure (HF) in this aging population.
  • Coronary heart disease (CHD) and stroke occur worldwide in all populations and in all races. More than 60% of these individuals have  hypertension, which is an important underlying cause of atrial fibrillation, a serious abnormal heart rhythm that is common in the age group 70–90; this condition requires treatment with a blood thinner, warfarin, to prevent strokes.

  • The main underlying cause for atrial fibrillation is hypertension and aging ( Atrial Fibrillation).

The processes involved in aging of the heart, aorta, and arteries need to be clarified. Changes in the media of the aorta caused by aging increase cardiac workload.
  • A review...

This is a preview of subscription content, log in to check access.



  1. Albert CM, Cook NR, Gaziano JM et al (2008) The effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299(17):2027–2036PubMedGoogle Scholar
  2. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898Google Scholar
  3. Davis BR, Kostis JB, Simpson LM et al (2008) Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial for the ALLHAT Collaborative Research Group. Circulation 118:2259–2267PubMedGoogle Scholar
  4. Hlatky MA, Boothroyd DB, Bravata DM et al (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. doi:10.1016/S0140-6736(09)60552-3PubMedGoogle Scholar
  5. Khan M Gabriel (2007) Beta blockers the cornerstone of cardiac drug therapy. In Cardiac Drug Therapy, seventh edition. Humana Press, New Jersey. Page 31 chapter beta blockersGoogle Scholar
  6. Meyer P, White M, Mujib M et al (2008) Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol 102(12):1681–1686PubMedGoogle Scholar
  7. Moura LM, Ramos SF, Zamorano JL et al (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49:554–561PubMedGoogle Scholar
  8. O’Rourke MF, Hashimoto J (2007) Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 50:1–13PubMedGoogle Scholar
  9. Pitt B, Reichek N, Willenbrock R et al (2003a) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E–left ventricular hypertrophy study. Circulation 108:1831PubMedGoogle Scholar
  10. Rossebø AB, Pedersen TR, Boman K et al for the SEAS Investigators (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343–1356Google Scholar

Suggested Reading

  1. Muslin AJ (2009) New insights into cardiac aging. Circulation 120:1654–1656, published onlinePubMedGoogle Scholar

Case Studies

  1. Chan KL, Teo K, Dumesnil JG et al for the ASTRONOMER Investigators (2010) Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) Trial. Circulation 121:306–314. ASTRONOMERGoogle Scholar
  2. Einhorn PT, Davis BR, Massie BM et al (2007) ALLHAT heart failure validation study: diagnosis and prognosis. Am Heart J 153:42–53. ALLHAT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialPubMedGoogle Scholar
  3. Flather MD, Shibata MC, Coats AJS et al SENIORS Investigators (2005) Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225. SENIORSPubMedGoogle Scholar
  4. Homocysteine lowering with folic acid and B vitamins in vascular disease (2006) N Engl J Med 354:1567–1577. HOPE-TOO: The Heart Outcomes Prevention Evaluation InvestigatorsGoogle Scholar
  5. Massie BM, Carson PE, McMurray JJ et al the I-PRESERVE Investigators (2008) Irbesartan in patients with heart failure and preserved ejection fraction. NEJM 359:2456–2467. I-PRESERVEGoogle Scholar
  6. Pitt B, Remme W, Zannad F et al (2003b) Eplerenone, a selective aldosterone blocker, in patients with left venticular dysfunction after myocardial infarction. New Eng J Med 348:1309–1321. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigatorsPubMedGoogle Scholar
  7. Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961–972. SYNTAXPubMedGoogle Scholar
  8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) JAMA 283:1967–1975. ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialGoogle Scholar
  9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288:2981–2997. ALLHATGoogle Scholar
  10. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (1999) N Engl J Med 341:709–717. RALES: The Randomized Aldactone Evaluation Study investigatorsGoogle Scholar
  11. Thiemann DR, Coresh J, Schulman SP et al (2000) Lack of benefit for IV thrombolysis in patients with MI who are older than 75 years. Circulation 101:2239PubMedGoogle Scholar
  12. van Veldhuisen DJ, Cohen-Solal A, Bohm M et al SENIORS Investigators (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol 53:2150–2158. SENIORSGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2011